vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Inspirato Inc (ISPO). Click either name above to swap in a different company.

Inspirato Inc is the larger business by last-quarter revenue ($55.5M vs $45.1M, roughly 1.2× Amarin Corp plc). Inspirato Inc runs the higher net margin — -8.1% vs -23.3%, a 15.1% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -19.6%). Over the past eight quarters, Inspirato Inc's revenue compounded faster (-11.4% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Inspirato Inc is a luxury travel and hospitality subscription service provider catering primarily to high-net-worth consumers across North America. It offers curated premium villa rentals, exclusive resort access, customized trip planning, and corporate travel incentive solutions for enterprise clients.

AMRN vs ISPO — Head-to-Head

Bigger by revenue
ISPO
ISPO
1.2× larger
ISPO
$55.5M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+26.6% gap
AMRN
7.0%
-19.6%
ISPO
Higher net margin
ISPO
ISPO
15.1% more per $
ISPO
-8.1%
-23.3%
AMRN
Faster 2-yr revenue CAGR
ISPO
ISPO
Annualised
ISPO
-11.4%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
AMRN
AMRN
ISPO
ISPO
Revenue
$45.1M
$55.5M
Net Profit
$-10.5M
$-4.5M
Gross Margin
31.4%
Operating Margin
35.5%
-8.0%
Net Margin
-23.3%
-8.1%
Revenue YoY
7.0%
-19.6%
Net Profit YoY
33.0%
-204.4%
EPS (diluted)
$-0.36

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
ISPO
ISPO
Q1 26
$45.1M
Q4 25
$49.2M
Q3 25
$49.7M
$55.5M
Q2 25
$72.7M
$63.1M
Q1 25
$42.0M
$65.9M
Q4 24
$62.3M
$63.1M
Q3 24
$42.3M
$69.1M
Q2 24
$67.5M
$67.4M
Net Profit
AMRN
AMRN
ISPO
ISPO
Q1 26
$-10.5M
Q4 25
$-1.2M
Q3 25
$-7.7M
$-4.5M
Q2 25
$-14.1M
$-5.3M
Q1 25
$-15.7M
$1.6M
Q4 24
$-48.6M
$-2.3M
Q3 24
$-25.1M
$4.3M
Q2 24
$1.5M
$-8.7M
Gross Margin
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
47.1%
Q3 25
44.7%
31.4%
Q2 25
69.2%
27.5%
Q1 25
59.8%
38.8%
Q4 24
-15.4%
34.7%
Q3 24
38.5%
71.5%
Q2 24
63.4%
24.0%
Operating Margin
AMRN
AMRN
ISPO
ISPO
Q1 26
35.5%
Q4 25
-12.9%
Q3 25
-22.4%
-8.0%
Q2 25
-22.0%
-8.3%
Q1 25
-39.9%
2.5%
Q4 24
-84.3%
-3.2%
Q3 24
-59.5%
9.8%
Q2 24
-0.8%
-22.8%
Net Margin
AMRN
AMRN
ISPO
ISPO
Q1 26
-23.3%
Q4 25
-2.5%
Q3 25
-15.6%
-8.1%
Q2 25
-19.4%
-8.4%
Q1 25
-37.4%
2.5%
Q4 24
-78.0%
-3.6%
Q3 24
-59.4%
6.3%
Q2 24
2.3%
-12.9%
EPS (diluted)
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
$0.00
Q3 25
$-0.02
$-0.36
Q2 25
$-0.03
$-0.42
Q1 25
$-0.04
$0.12
Q4 24
$-0.12
$0.98
Q3 24
$-0.06
$0.62
Q2 24
$0.00
$-2.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
ISPO
ISPO
Cash + ST InvestmentsLiquidity on hand
$307.8M
$13.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-134.0M
Total Assets
$645.8M
$228.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
ISPO
ISPO
Q1 26
$307.8M
Q4 25
$302.6M
Q3 25
$286.6M
$13.7M
Q2 25
$298.7M
$16.7M
Q1 25
$281.8M
$16.4M
Q4 24
$294.2M
$21.8M
Q3 24
$305.7M
$13.5M
Q2 24
$306.7M
$18.8M
Stockholders' Equity
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
$459.3M
Q3 25
$458.9M
$-134.0M
Q2 25
$464.9M
$-129.7M
Q1 25
$473.7M
$-125.2M
Q4 24
$486.2M
$-129.9M
Q3 24
$531.4M
$-134.6M
Q2 24
$551.9M
$-35.2M
Total Assets
AMRN
AMRN
ISPO
ISPO
Q1 26
$645.8M
Q4 25
$670.8M
Q3 25
$659.8M
$228.3M
Q2 25
$670.1M
$252.6M
Q1 25
$655.7M
$270.1M
Q4 24
$685.3M
$273.9M
Q3 24
$750.6M
$273.3M
Q2 24
$799.9M
$301.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
ISPO
ISPO
Operating Cash FlowLast quarter
$-2.2M
Free Cash FlowOCF − Capex
$-3.0M
FCF MarginFCF / Revenue
-5.4%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-31.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
$15.3M
Q3 25
$-12.7M
$-2.2M
Q2 25
$16.6M
$1.1M
Q1 25
$-12.5M
$-6.6M
Q4 24
$-13.3M
$-15.8M
Q3 24
$-2.4M
$-13.7M
Q2 24
$-2.7M
$-1.8M
Free Cash Flow
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
Q3 25
$-3.0M
Q2 25
$468.0K
Q1 25
$-7.5M
Q4 24
$-21.2M
Q3 24
$-14.8M
Q2 24
$-3.7M
FCF Margin
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
Q3 25
-5.4%
Q2 25
0.7%
Q1 25
-11.4%
Q4 24
-33.7%
Q3 24
-21.5%
Q2 24
-5.5%
Capex Intensity
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
Q3 25
1.4%
Q2 25
1.0%
Q1 25
1.3%
Q4 24
8.7%
Q3 24
1.6%
Q2 24
2.8%
Cash Conversion
AMRN
AMRN
ISPO
ISPO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
-4.09×
Q4 24
Q3 24
-3.16×
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

ISPO
ISPO

Residence And Hotel Travel$25.9M47%
Subscription$19.4M35%
Experiences And Bespoke Travel$8.0M14%
Rewards And Other Revenue$2.3M4%

Related Comparisons